$3.85+0.14 (+3.77%)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.85. Wall Street consensus targets $11.75 (4 analysts), implying a +205.2% move over the next 12 months. The stock is currently 20% below its 52-week high of $4.83, remaining 2.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...
X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are tying this change closely to expectations around mavorixafor in WHIM syndrome and primary chronic neutropenia, and to how much of that story is already reflected in the stock. As you read on, you will see how different analysts are framing this shift and what to watch as the narrative...
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
With a stock price of $4.41, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is among the 10 Unrivaled Penny Stocks to Buy Now. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) reported first-quarter revenue of $2.71 million on May 6, compared with analyst consensus estimates of $3.2 million. Management stated that its top priority remains the execution and enrollment of the pivotal Phase 3 […]
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?